Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Allergy & Immunology
•
Asthma
How do you decide when to add a second biologic agent to a patient’s asthma treatment who has either not responded or had a partial response to dupilumab, omalizumab, mepolizumab, or tezepelumab?
Related Questions
Is there a role for biologics to improve lung function in patients who have severe asthma with daily symptoms and reduced lung function but do not experience frequent exacerbations?
When would you recommend prescribing an asthmatic patient budesonide/salbutamol rather than budesonide/formoterol?
Are there concerns with combining anti-IL5 biologics (mepolizumab or benralizumab) for severe asthma with other biologics for RA (e.g. TNFi)?
What factors do you consider prior to offering a trial of ICS/LABA therapy versus a methacholine challenge test in patients with suspected asthma but normal pulmonary function testing?
What is your approach to inhaler therapy in a patient with asthma who cannot be on an inhaled corticosteroid due to ocular disease?
Is methacholine challenge on its way out?
What is your preferred biologic for an asthmatic patient with a T2 low phenotype and who is a smoker?
Do you feel high dose Symbicort or Dulera is appropriate to use for SMART despite these doses not being studied in clinical trials?
How do you factor smoking history into biologic selection for asthma since the clinical trials generally excluded these patients?
What is your preferred biologic in children and adolescents with T2 high asthma?
